Jim Palma, Executive Director at TargetCancer Foundation discusses a new clinical trial called TRACK (TargetRare Cancer Knowledge). Supported by Bayer and Foundation Medicine, TRACK provides rare cancer patients with access to genomic testing, personalized treatment recommendations and information via a virtual panel of rare cancer experts. This approach ensures that patients have access to this trial, even if they do not live near a clinical trial site and can socially distance due to COVID-19.
Since joining TargetCancer Foundation in 2010, Jim Palma has overseen its growth from a small start-up to a nationally recognized foundation supporting comprehensive rare cancer research programs and patient support services. Prior to joining TargetCancer Foundation, he spent eleven years at Fidelity Investments in Boston, MA.
Jim is Vice Chairman of the Board of Directors of the National Organization for Rare Disorders (NORD), and is a founding Co-Chair of the NORD Rare Cancers Coalition. In addition, Jim is a Steering Committee member at the GI Cancers Alliance, and the Global Cholangiocarcinoma Alliance. Jim completed studies at the Institute for Nonprofit Management and Leadership at the Questrom School of Business at Boston University, and received his B.A. from Loyola University Maryland.